KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Payables (2016 - 2026)

Gsk has reported Payables over the past 18 years, most recently at -$19.7 billion for Q1 2026.

  • For Q1 2026, Payables fell 1.58% year-over-year to -$19.7 billion; the TTM value through Mar 2026 reached -$19.7 billion, down 1.58%, while the annual FY2025 figure was -$24.5 billion, 207.79% down from the prior year.
  • Payables for Q1 2026 was -$19.7 billion at Gsk, up from -$24.5 billion in the prior quarter.
  • Over five years, Payables peaked at $23.7 billion in Q4 2022 and troughed at -$25.0 billion in Q3 2025.
  • A 5-year average of -$12.5 billion and a median of -$19.7 billion in 2026 define the central range for Payables.
  • Biggest five-year swings in Payables: surged 78.55% in 2022 and later plummeted 289.45% in 2023.
  • Year by year, Payables stood at $23.7 billion in 2022, then dropped by 2.34% to $23.2 billion in 2023, then decreased by 1.98% to $22.7 billion in 2024, then plummeted by 207.79% to -$24.5 billion in 2025, then grew by 19.67% to -$19.7 billion in 2026.
  • Business Quant data shows Payables for GSK at -$19.7 billion in Q1 2026, -$24.5 billion in Q4 2025, and -$25.0 billion in Q3 2025.